Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK Limited

Alan Xiangdong Wang

Paul Michael Scola

Makonen Belema

Nicholas A Meanwell

Li-Qiang Sun

Ny Sin

John F Kadow

Piyasena Hewawasam

Sing-Yuen Sit

Yan Chen

John A Bender

Mark George Saulnier

Omar D Lopez

Yong Tu

Ningning Xu

Stanley V D'Andrea

David Bertil Frennesson

Ramkumar Rajamani

Samayamunthula Venkata Satya Arun Kumar Gupta

Robert A Fridell

Barbara Zhizhen Zheng

B Narasimhulu Naidu

Annapurna Pendri

Gan Wang

Manoj Patel

Van N Nguyen

Robert G Gentles

Kyle E Parcella

Kevin M Peese

Zhong Yang

Brett R Beno

Selvakumar Kumaravel

Christiana Iwuagwu

Kap-Sun Yeung

David R Langley

Eric P Gillis

Qian Zhao

Eric Mull

Katharine A Grant-Young

Timothy P Connolly

Brian Lee Venables

Manoranjan Panda

Michael S Bowsher

Srinivasan Thangathirupathy

Min Gao

Hasibur Rahaman

Guo Li

Pulicharla Nagalakshmi

Rajesh Onkardas Bora

Zhaoxing Meng

Juliang Zhu

Julie A Lemm

Ying-Kai Wang

Pothukanuri Srinivasu

Mallikarjuna Rao Mettu

Donald R O'Boyle, Ii

Jin-Hua Sun

Roshan Yadavrao Nimje

Shilpa Maheshwarappa Holehatti

Indasi J Gopi Kumar

Suresh Kumar Ponugupati

Indasi Gopi Kumar

Suresh Babu

Ponugupati Suresh Kumar

Chunfu Wang

Davidb Frennesson

Suresh Kumar Punugupati

Donald R O'BOYLE Ii

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. 

Inhibitors of human immunodeficiency virus replication

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Compounds useful as immunomodulators

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: 

Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus

Hepatitis C virus inhibitors are disclosed having the general formula: 

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Growing community of inventors

Wallingford, CT, United States of America

Alan Xiangdong Wang